Oncology Corporate Profile
Nereus Pharmaceuticals is an innovative drug discovery and development company pursuing untapped sources of chemical diversity through identifying drug candidates derived from marine microbes. With unmatched expertise in marine microbiology and integrated technologies to identify and synthesize novel biologically active compounds, the Company's two oncology drug candidates are in Phase I clinical trials. Plinabulin (NPI-2358), a tumor vascular disrupting agent, is being evaluated for solid tumors, and a proteasome inhibitor NPI-0052 is being developed for solid tumors, lymphomas and multiple myeloma.
|Brand / Product||Class||Area of Study||Phase||Partnership|
|plinabulin / NPI-2358||vascular disrupting agent||Non Small Cell Lung Cancer (NSCLC)||II|
|NPI-0052||proteasome inhibitor||Multiple Myeloma||I|
|plinabulin / NPI-2358||vascular disrupting agent||Various cancer types||I|
|NPI-0052||proteasome inhibitor||Various cancer types||I|
View additional information on product candidates here »